Anixa Biosciences Inc (NASDAQ:ANIX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Anixa Biosciences Inc (NASDAQ:ANIX) have received a consensus recommendation of “Hold” from the five brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $8.50.

A number of analysts have recently weighed in on the stock. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a report on Friday. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research report on Wednesday, April 8th. Wall Street Zen cut Anixa Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday.

Anixa Biosciences Trading Down 2.0%

Shares of ANIX stock traded down $0.05 on Friday, reaching $2.43. The company’s stock had a trading volume of 34,881 shares, compared to its average volume of 138,590. The stock’s fifty day simple moving average is $2.78 and its 200-day simple moving average is $3.10. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46. The company has a market capitalization of $81.48 million, a price-to-earnings ratio of -7.84 and a beta of 0.59.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. Equities research analysts forecast that Anixa Biosciences will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently modified their holdings of the stock. Bank of America Corp DE raised its position in Anixa Biosciences by 1.7% in the 3rd quarter. Bank of America Corp DE now owns 213,955 shares of the company’s stock worth $706,000 after purchasing an additional 3,645 shares during the period. GSA Capital Partners LLP boosted its holdings in Anixa Biosciences by 4.9% during the 3rd quarter. GSA Capital Partners LLP now owns 81,897 shares of the company’s stock valued at $270,000 after acquiring an additional 3,790 shares during the period. Prosperity Wealth Management Inc. grew its position in Anixa Biosciences by 14.5% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 41,800 shares of the company’s stock valued at $138,000 after acquiring an additional 5,300 shares during the last quarter. Geode Capital Management LLC increased its stake in Anixa Biosciences by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 350,915 shares of the company’s stock worth $1,095,000 after purchasing an additional 7,271 shares during the period. Finally, Renaissance Technologies LLC lifted its position in shares of Anixa Biosciences by 13.6% during the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after purchasing an additional 7,300 shares during the last quarter. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.